跨导管大动脉植入和更换:最新进展和前景
Milos Brankovic1, Abhishek Sharma2
1Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
Journal of clinical medicine
|March 27, 2025
概括
透导管大动脉置换 (TAVR) 改变了大动脉狭窄症的治疗方法,即使在低风险患者中也被证明是安全有效的. 持续的进展旨在提高这种微创手术的长期结果.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 医疗器械技术 医疗器械技术
背景情况:
- 过导管大动脉置换 (TAVR) 已成为大动脉狭窄的主要治疗方法.
- 自2000年代初以来,TAVR技术,技巧和患者选择方面取得了重大进展.
- TAVR已经证明改善了生存率和生活质量,并将其应用于低风险患者群体.
研究的目的:
- 审查TAVR设备和大动脉狭窄症治疗策略的最新创新.
- 讨论TAVR的挑战和未来前景,特别是关于年轻患者的长期结果.
- 探索新兴技术,旨在优化TAVR后的长期结果.
主要方法:
- 对TAVR进展的文献综述.
- 分析当前的TAVR设备技术和程序技术.
- 探索研究的长期成果和未来的技术发展.
主要成果:
- TAVR已经发生了显著的进化,为大动脉狭窄提供了更好的安全性和有效性.
- 该程序在高风险和低风险的手术患者中都显示出好处.
- 年轻人群体的长期耐用性和结果仍然是持续研究和技术开发的关键领域.
结论:
- TAVR代表了对主动脉狭窄的管理的重大进步,具有经过证明的短期和中期益处.
- 解决对日益增长的年轻TAVR受益者队伍的长期影响至关重要.
- 新兴技术有望提高TAVR的耐用性和长期疗效.
关键词:
塔维 (TAVI) 是一个古老的城市.在TAVRR中,我们可以看到.大动脉狭窄症 (大动脉狭窄症)设备技术 设备技术 设备技术结构性心脏病是一种心脏病.穿过导管的大动脉植入装置.通过导管更换大动脉门.试验 试验 试验 试验更新 更新 更新 更新 更新门的设计设计.更多相关视频
08:50Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
Published on: March 26, 2018
11.6K
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
2.7K
相关概念视频
Mitral Stenosis III: Medical Management
535
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
535
Aortic Regurgitation III: Medical Management
598
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
598
Heart Failure VI: Adjunct Therapies
632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
